170 related articles for article (PubMed ID: 29471588)
1. Brief Report: Attenuated Effectiveness of Tumor Necrosis Factor Inhibitors for Anti-Human T Lymphotropic Virus Type I Antibody-Positive Rheumatoid Arthritis.
Suzuki T; Fukui S; Umekita K; Miyamoto J; Umeda M; Nishino A; Okada A; Koga T; Kawashiri SY; Iwamoto N; Ichinose K; Tamai M; Fujikawa K; Aramaki T; Mizokami A; Matsuoka N; Ueki Y; Eguchi K; Sato S; Hidaka T; Origuchi T; Okayama A; Kawakami A; Nakamura H
Arthritis Rheumatol; 2018 Jul; 70(7):1014-1021. PubMed ID: 29471588
[TBL] [Abstract][Full Text] [Related]
2. Treatment with anti–tumor necrosis factor biologic agents in human T lymphotropic virus type I–positive patients with rheumatoid arthritis.
Umekita K; Hidaka T; Miyauchi S; Ueno S; Kubo K; Takajo I; Hashiba Y; Kai Y; Nagatomo Y; Okayama A
Arthritis Care Res (Hoboken); 2014 May; 66(5):788-92. PubMed ID: 24127184
[TBL] [Abstract][Full Text] [Related]
3. Use of anti-tumor necrosis factor biologics in the treatment of rheumatoid arthritis does not change human T-lymphotropic virus type 1 markers: a case series.
Umekita K; Umeki K; Miyauchi S; Ueno S; Kubo K; Kusumoto N; Takajo I; Nagatomo Y; Okayama A
Mod Rheumatol; 2015 Sep; 25(5):794-7. PubMed ID: 24252020
[TBL] [Abstract][Full Text] [Related]
4. Effectiveness and safety of non-tumor necrosis factor inhibitor therapy for anti-human T-cell leukemia virus type 1 antibody-positive rheumatoid arthritis.
Endo Y; Fukui S; Umekita K; Suzuki T; Miyamoto J; Morimoto S; Shimizu T; Koga T; Kawashiri SY; Iwamoto N; Ichinose K; Tamai M; Origuchi T; Okada A; Fujikawa K; Mizokami A; Matsuoka N; Aramaki T; Ueki Y; Eguchi K; Kariya Y; Hashiba Y; Hidaka T; Okayama A; Kawakami A; Nakamura H
Mod Rheumatol; 2021 Sep; 31(5):972-978. PubMed ID: 33161771
[TBL] [Abstract][Full Text] [Related]
5. Anti-Ro/SSA antibodies are an independent factor associated with an insufficient response to tumor necrosis factor inhibitors in patients with rheumatoid arthritis.
Matsudaira R; Tamura N; Sekiya F; Ogasawara M; Yamanaka K; Takasaki Y
J Rheumatol; 2011 Nov; 38(11):2346-54. PubMed ID: 21965648
[TBL] [Abstract][Full Text] [Related]
6. Tumor necrosis factor alpha inhibitors have no effect on a human T-lymphotropic virus type-I (HTLV-I)-infected cell line from patients with HTLV-I-associated myelopathy.
Fukui S; Nakamura H; Takahashi Y; Iwamoto N; Hasegawa H; Yanagihara K; Nakamura T; Okayama A; Kawakami A
BMC Immunol; 2017 Feb; 18(1):7. PubMed ID: 28158970
[TBL] [Abstract][Full Text] [Related]
7. Differential response of the rheumatoid factor and anticitrullinated protein antibodies during adalimumab treatment in patients with rheumatoid arthritis.
Bos WH; Bartelds GM; Wolbink GJ; de Koning MH; van de Stadt RJ; van Schaardenburg D; Dijkmans BA; Nurmohamed MT
J Rheumatol; 2008 Oct; 35(10):1972-7. PubMed ID: 18785316
[TBL] [Abstract][Full Text] [Related]
8. Effect of HTLV-1 Infection on the Clinical Course of Patients with Rheumatoid Arthritis.
Umekita K
Viruses; 2022 Jul; 14(7):. PubMed ID: 35891440
[TBL] [Abstract][Full Text] [Related]
9. Fucoidan therapy decreases the proviral load in patients with human T-lymphotropic virus type-1-associated neurological disease.
Araya N; Takahashi K; Sato T; Nakamura T; Sawa C; Hasegawa D; Ando H; Aratani S; Yagishita N; Fujii R; Oka H; Nishioka K; Nakajima T; Mori N; Yamano Y
Antivir Ther; 2011; 16(1):89-98. PubMed ID: 21311112
[TBL] [Abstract][Full Text] [Related]
10. Real-world Effectiveness of Biologic Disease-modifying Antirheumatic Drugs for the Treatment of Rheumatoid Arthritis After Etanercept Discontinuation in the United Kingdom, France, and Germany.
Li N; Betts KA; Messali AJ; Skup M; Garg V
Clin Ther; 2017 Aug; 39(8):1618-1627. PubMed ID: 28729087
[TBL] [Abstract][Full Text] [Related]
11. The Association of Increase of Human T-Cell Leukemia Virus Type-1 (HTLV-1) Proviral Load (PVL) With Infection in HTLV-1-Positive Patients With Rheumatoid Arthritis: A Longitudinal Analysis of Changes in HTLV-1 PVLs in a Single Center Cohort Study.
Iwamoto N; Araki T; Umetsu A; Takatani A; Aramaki T; Ichinose K; Terada K; Hirakata N; Ueki Y; Kawakami A; Eguchi K
Front Immunol; 2022; 13():887783. PubMed ID: 35603142
[TBL] [Abstract][Full Text] [Related]
12. Disease Activity Score 28 (DAS28) using C-reactive protein underestimates disease activity and overestimates EULAR response criteria compared with DAS28 using erythrocyte sedimentation rate in a large observational cohort of rheumatoid arthritis patients in Japan.
Matsui T; Kuga Y; Kaneko A; Nishino J; Eto Y; Chiba N; Yasuda M; Saisho K; Shimada K; Tohma S
Ann Rheum Dis; 2007 Sep; 66(9):1221-6. PubMed ID: 17369281
[TBL] [Abstract][Full Text] [Related]
13. HTLV-1-associated arthropathy treated with anti-TNF-alpha agent.
Frenzel L; Moura B; Marcais A; Chapdelaine H; Hermine O
Joint Bone Spine; 2014 Jul; 81(4):360-1. PubMed ID: 24289962
[TBL] [Abstract][Full Text] [Related]
14. Anti-HTLV antibody profiling reveals an antibody signature for HTLV-I-associated myelopathy/tropical spastic paraparesis (HAM/TSP).
Burbelo PD; Meoli E; Leahy HP; Graham J; Yao K; Oh U; Janik JE; Mahieux R; Kashanchi F; Iadarola MJ; Jacobson S
Retrovirology; 2008 Oct; 5():96. PubMed ID: 18937847
[TBL] [Abstract][Full Text] [Related]
15. Highest clinical effectiveness of rituximab in autoantibody-positive patients with rheumatoid arthritis and in those for whom no more than one previous TNF antagonist has failed: pooled data from 10 European registries.
Chatzidionysiou K; Lie E; Nasonov E; Lukina G; Hetland ML; Tarp U; Gabay C; van Riel PL; Nordström DC; Gomez-Reino J; Pavelka K; Tomsic M; Kvien TK; van Vollenhoven RF
Ann Rheum Dis; 2011 Sep; 70(9):1575-80. PubMed ID: 21571731
[TBL] [Abstract][Full Text] [Related]
16. Population differences in immune marker profiles associated with human T-lymphotropic virus type I infection in Japan and Jamaica.
Birmann BM; Breen EC; Stuver S; Cranston B; Martínez-Maza O; Falk KI; Okayama A; Hanchard B; Mueller N; Hisada M
Int J Cancer; 2009 Feb; 124(3):614-21. PubMed ID: 18989900
[TBL] [Abstract][Full Text] [Related]
17. Drug survival, efficacy and toxicity of monotherapy with a fully human anti-tumour necrosis factor-alpha antibody compared with methotrexate in long-standing rheumatoid arthritis.
Barrera P; van der Maas A; van Ede AE; Kiemeney BA; Laan RF; van de Putte LB; van Riel PL
Rheumatology (Oxford); 2002 Apr; 41(4):430-9. PubMed ID: 11961174
[TBL] [Abstract][Full Text] [Related]
18. HTLV-I serostatus of mothers of patients with adult T-cell leukemia and HTLV-I-associated myelopathy/tropical spastic paraparesis.
Bartholomew C; Jack N; Edwards J; Charles W; Corbin D; Cleghorn FR; Blattner WA
J Hum Virol; 1998; 1(4):302-5. PubMed ID: 10195256
[TBL] [Abstract][Full Text] [Related]
19. Disease activity improvement in rheumatoid arthritis treated with tumor necrosis factor-α inhibitors correlates with increased soluble Fas levels.
Romano E; Terenzi R; Manetti M; Peruzzi F; Fiori G; Nacci F; Bellando-Randone S; Matucci-Cerinic M; Guiducci S
J Rheumatol; 2014 Oct; 41(10):1961-5. PubMed ID: 25179850
[TBL] [Abstract][Full Text] [Related]
20. HAS-Flow May Be an Adequate Method for Evaluating Human T-Cell Leukemia Virus Type 1 Infected Cells in Human T-Cell Leukemia Virus Type 1-Positive Rheumatoid Arthritis Patients Receiving Antirheumatic Therapies: A Retrospective Cross-Sectional Observation Study.
Umekita K; Hashikura Y; Takaki A; Kimura M; Kawano K; Iwao C; Miyauchi S; Kawaguchi T; Matsuda M; Hashiba Y; Hidaka T
Viruses; 2023 Feb; 15(2):. PubMed ID: 36851682
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
